synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Breeders strive to produce tomato plants with improved yield, shelf life, size, and resistance to environmental pressures, including disease. These efforts have yielded unintended negative consequences on various fruit attributes. For instance, linkage drag, the introduction of an undesired trait during backcrossing, has altered the metabolism of the fruit. This trait is physically close to the desired allele along the chromosome. Breeding for traits like larger fruit has thus unintentionally altered nutritional value and flavor. Breeders have turned to wild tomato species as a source of alleles to introduce beneficial traits into modern varieties. For example, wild relatives may possess higher amounts of fruit solids (associated with greater sugar content), or resistance to diseases such as the early blight pathogen Alternaria solani. However, this tactic has limitations, since selection for traits such as pathogen resistance can negatively impact other favorable traits such as fruit production.
== PhIP and cooking methods == Studies examining the amount of PhIP in cooked meats have shown that high levels of exposure are possible. Doneness levels of meat (rare, medium, well-done, and very well-done) are factors in the development of PhIP. Methods to reduce formation of PhIP in meats include decreasing the temperature at which the meat is cooked, decreasing the length of cooking time, pre-heating meat in the microwave oven (which reduces creatine), and marinating the meat.
== Functions and binding properties == Such a broad pattern in gene expression over such a wide range of sensory and non-sensory fluids or tissues is in strong agreement with a very general basic function for this gene family, i.e. in relation with lipid transport and metabolism. A role of CSPs in general immunity, insecticide resistance and xenobiotic degradation has been recently brought up by Xuan et al. (2015), who showed a drastic and remarkable up-regulation of CSP genes in many various tissues over exposure to abamectin insecticide molecule [32]. Increased load of CSPs (pherokines) in fly hemolymph is observed after microbial or viral infection [33]. The particular role of CSP proteins in lipid transport in relation with insecticide resistance has been brought up by Liu et al. (2016) in whiteflies [34]. Liu et al. showed insecticide-mediated up regulation and interaction of the protein with C18-lipid (linoleic acid), suggesting a metabolic role of CSP in insect defense rather than olfaction or chemical communication [34]. The first member of this soluble protein family has been reported by Nomura et al. (1982) as up-regulated factor (p10) in the regenerating legs of the American cockroach Periplaneta americana [35]. The same protein was identified in the antennae and legs from P. americana at the adult sexually mature stage with some apparent differences between males and females, rather suggesting a “chemodevol” function for this protein, contributing both to tissue development and recognition of sex-specific signals such as sex pheromones [2].
retort A laboratory apparatus used for the distillation or dry distillation of chemical substances, traditionally consisting of a spherical vessel with a long, downward-pointing neck that conducts the condensed vapors produced by distillation into a separate collection vessel.
Sources: en.wikipedia.org
As an analytical technique, RIS is useful based on some of its working operations – they include extremely low detection limit so that mass of samples could be identified up to the order of 10−15, the extremely high sensitivity and elemental selectivity useful in micro- and trace analysis when coupled with mass spectrometers, and ability of the pulsed laser ion source to produce pure isobaric ion beams. A major advantage of using resonance ionization is that it is a highly selective ionization mode; it is able to target a single type of atom among a background of many types of atoms, even when said background atoms are much more abundant than the target atoms. In addition, resonance ionization incorporates the high selectivity that is desired in spectroscopy methods with ultrasensitivity, thus making resonance ionization useful when analyzing complex samples with several atomic components. Resonance ionization spectroscopy (RIS) thus has a wide range of research and industrial applications. These include characterizing the diffusion and chemical reaction of free atoms in a gas medium, solid state surface analysis using direct sampling, studying the degree of concentration variations in a dilute vapor, detecting the allowable limits of number of particles needed in a semiconductor device, and estimating the flux of solar neutrinos on Earth.
The XM913 is an experimental American chain gun produced at Picatinny Arsenal. The cannon is a larger and more modern version of the 35 mm Bushmaster III chain gun, which itself is a larger version of the 25 mm M242 Bushmaster cannon. Although its shells, 50 x 228 mm, are twice the diameter of the 25×137mm cartridge of the M242, the 50mm cannon is not much longer than the smaller weapon. The overall lengths of the 25mm cannon and 50mm cannon are 105.2 inches (267 cm) and 117.7 inches (299 cm), respectively; while the portion of the gun that intrudes into the turret are 30.0 inches (76 cm) and 40.1 inches (102 cm), respectively. The XM913 has been selected as the primary weapon on the US Army's new Next Generation Combat Vehicle, the XM30 MICV.
Aggregate widths can be determined by CP/MAS NMR developed by Innventia AB, Sweden, which also has been demonstrated to work for nanocellulose (enzymatic pre-treatment). An average width of 17 nm has been measured with the NMR-method, which corresponds well with SEM and TEM. Using TEM, values of 15 nm have been reported for nanocellulose from carboxymethylated pulp. However, thinner fibrils can also be detected. Wågberg et al. reported fibril widths of 5–15 nm for a nanocellulose with a charge density of about 0.5 meq./g. The group of Isogai reported fibril widths of 3–5 nm for TEMPO-oxidized cellulose having a charge density of 1.5 meq./g. Pulp chemistry has a significant influence on nanocellulose microstructure. Carboxymethylation increases the numbers of charged groups on the fibril surfaces, making the fibrils easier to liberate and results in smaller and more uniform fibril widths (5–15 nm) compared to enzymatically pre-treated nanocellulose, where the fibril widths were 10–30 nm.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.